In 2012, the FDA approved the first new prescription weight loss drug in thirteen years: lorcaserin, marketed as Belviq. Available to patients in the US since June 2013 in a…
Blog
Learn about recent news
Learn about recent news
In 2012, the FDA approved the first new prescription weight loss drug in thirteen years: lorcaserin, marketed as Belviq. Available to patients in the US since June 2013 in a…
The U.S Department of Education recently announced new changes in how colleges are to handle sexual assault and sexual harassment complaints. These changes to Title IX, the federal regulation on…
If you thought the bad old days of Mean Streets-type street crime were over, think again. The COVID-19 coronavirus pandemic has caused automobile vehicle thefts to spike 63 percent in…
Mr. Floyd’s death sent shockwaves around the country, and around the world, in a way not seen since Watts, Bloody Sunday, Detroit, the University of Mississippi, and other violent civil…
An important part of any successful business is having a safe working environment for your employees. When they feel as if they can safely do their job, they’re happy and…
Healthcare policy has quickly shifted to a central focal point in our world, and more people are facing obstacles in care that have been commonly unknown. Patient abandonment is far…
As the coronavirus has changed daily life for populations worldwide, it has brought out the best in many people who have banded together (while remaining physically separated) to give aid…
Heartburn Heaven As recently as August 2019, the ranitidine market was tipped to top a gut-gripping US$ 485.4 million by 2026. Introduced in 1981, this popular antacid – better known…
Pharmaceutical giant Johnson & Johnson raised the proverbial white flag, at least to an extent, when it said it would no longer sell its controversial baby powder in the United…
New York Governor Andrew Cuomo already made headlines by approving a sweeping child sexual abuse law which could provide relief to thousands of victims. Cuomo made headlines again by further…